logo
‘Ticking timebomb': sea acidity has reached critical levels, threatening entire ecosystems

‘Ticking timebomb': sea acidity has reached critical levels, threatening entire ecosystems

Yahoo7 hours ago

The world's oceans are in worse health than realised, scientists have said today, as they warn that a key measurement shows we are 'running out of time' to protect marine ecosystems.
Ocean acidification, often called the 'evil twin' of the climate crisis, is caused when carbon dioxide is rapidly absorbed by the ocean, where it reacts with water molecules leading to a fall in the pH level of the seawater. It damages coral reefs and other ocean habitats and, in extreme cases, can dissolve the shells of marine creatures.
Until now, ocean acidification had not been deemed to have crossed its 'planetary boundary'. The planetary boundaries are the natural limits of key global systems – such as climate, water and wildlife diversity – beyond which their ability to maintain a healthy planet is in danger of failing. Six of the nine had been crossed already, scientists said last year.
However, a new study by the UK's Plymouth Marine Laboratory (PML), the Washington-based National Oceanic and Atmospheric Administration and Oregon State University's Co-operative Institute for Marine Resources Studies found that ocean acidification's 'boundary' was also reached about five years ago.
'Ocean acidification isn't just an environmental crisis – it's a ticking timebomb for marine ecosystems and coastal economies,' said PML's Prof Steve Widdicombe, who is also co-chair of the Global Ocean Acidification Observing Network.
The study drew on new and historical physical and chemical measurements from ice cores, combined with advanced computer models and studies of marine life, which gave the scientists an overall assessment of the past 150 years.
It found that by 2020 the average ocean condition worldwide was already very close to – and in some regions beyond – the planetary boundary for ocean acidification. This is defined as when the concentration of calcium carbonate in seawater is more than 20% below preindustrial levels.
The deeper in the ocean they looked, the worse the findings were, the scientists said. At 200 metres below the surface, 60% of global waters had breached the 'safe' limit for acidification.
'Most ocean life doesn't just live at the surface,' said PML's Prof Helen Findlay. 'The waters below are home to many more different types of plants and animals. Since these deeper waters are changing so much, the impacts of ocean acidification could be far worse than we thought.'
This had, she added, huge implications for important underwater ecosystems such as tropical and even deep-sea coral reefs that provided essential habitats and nursery grounds for the young of many species.
As pH levels drop, calcifying species such as corals, oysters, mussels and tiny molluscs known as sea butterflies struggle to maintain their protective structures, leading to weaker shells, slower growth, reduced reproduction and decreased survival rates.
Related: Surge in marine heatwaves costs lives and billions in storm damage – study
The authors underlined that decreasing CO2 emissions was the only way to deal with acidification globally, but that conservation measures could and should focus on the regions and species that were most vulnerable.
Jessie Turner, director of the International Alliance to Combat Ocean Acidification, who was not involved in the study, said: 'This report makes it clear: we are running out of time and what we do – or fail to do – now is already determining our future.
'We are coming to terms with an existential threat while grappling with the difficult reality that much suitable habitat for key species has already been lost. It's clear that governments can no longer afford to overlook acidification in mainstream policy agendas,' she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Ticking time bomb': Ocean acidity crosses vital threshold, study finds
‘Ticking time bomb': Ocean acidity crosses vital threshold, study finds

Yahoo

time14 minutes ago

  • Yahoo

‘Ticking time bomb': Ocean acidity crosses vital threshold, study finds

The deep oceans have crossed a crucial boundary that threatens their ability to provide the surface with food and oxygen, a new study finds. Nearly two-thirds of the ocean below 200 meters, or 656 feet, as well as nearly half of that above, have breached 'safe' levels of acidity, according to findings published on Monday in Global Change Biology. The fall in ocean pH is 'a ticking time bomb for marine ecosystems and coastal economies,' Steve Widdicombe, director of science at the United Kingdom's Plymouth Marine Laboratory (PML), said in a statement. The study was funded in part by the National Oceanographic and Atmospheric Administration (NOAA), a federal agency that has been targeted for steep cuts by the Trump White House, in large part because of its role in investigating climate change. Some of the biggest changes in deep water are happening off the coast of western North America, home to extensive crab and salmon fisheries, the study found. The core problem is one scientists have warned about for a long time: the continued global burning of fossil fuels, which releases carbon dioxide — an acid when dissolved in water — is making the seas and oceans more acidic. Or, technically, it's making them less basic, which is to say: Less hospitable to species such as corals and clams that form the foundation of the ocean's ecosystem. 'Most ocean life doesn't just live at the surface — the waters below are home to many more different types of plants and animals,' lead author Helen Findlay of PML. 'Since these deeper waters are changing so much, the impacts of ocean acidification could be far worse than we thought.' As of five years ago, Findlay's study noted, the oceans may have crossed a critical threshold in which oceanic levels of calcium carbonate — the main ingredient in limestones, and also the shells of those animals — fell to more than 20 percent below pre-industrial levels. If true, that shift would mean the Earth has passed seven out of nine of the critical 'planetary boundaries' needed to maintain its ecosystem, as the Potsdam Institute for Climate Impact Research found last year. That shift, Widdicombe of the Marine Lab said, means 'we're witnessing the loss of critical habitats that countless marine species depend on.' 'From the coral reefs that support tourism to the shellfish industries that sustain coastal communities,' he added, 'we're gambling with both biodiversity and billions in economic value every day that action is delayed.' The further implications are even more serious. The reasons for the ocean's rise in acid, or fall in base, is that its waters have absorbed about one-third of all the carbon dioxide released by surface burning of coal, oil and gas. But the more carbon dioxide it absorbs, the lower its ability to absorb more — meaning faster warming on the surface. Making that dynamic even more dramatic, seas and oceans have also absorbed 90 percent of the global heating that the Earth's surface would have otherwise experienced, according to NASA. In addition to absorbing heat and carbon dioxide, the ocean also provides 50 percent of the Earth's oxygen — which comes from the very marine ecosystems that warming and acidification are threatening. Ecosystem loss and fossil fuel burning mean that levels of oxygen below the surface are decreasing, as, more slowly, is oxygen above the surface. —Updated at 12:37 p.m. EDT Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Yahoo

time26 minutes ago

  • Yahoo

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@

SpaceX delays launch of private Ax-4 astronauts to ISS to June 11. Here's how to watch it live.
SpaceX delays launch of private Ax-4 astronauts to ISS to June 11. Here's how to watch it live.

Yahoo

timean hour ago

  • Yahoo

SpaceX delays launch of private Ax-4 astronauts to ISS to June 11. Here's how to watch it live.

When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX will launch four astronauts to the International Space Station (ISS) on the private Ax-4 mission Wednesday morning (June 11), and you can watch the action live. Ax-4 is scheduled to lift off atop a Falcon 9 rocket from NASA's Kennedy Space Center in Florida on Wednesday at 8:00 a.m. EDT (1200 GMT). That's a one-day delay; SpaceX had been targeting Tuesday morning (June 10) but pushed things back due to expected high winds in the area. You can watch the launch live here at courtesy of SpaceX and Axiom Space, the Houston-based company that organized the mission. The webcast will be at the top of this story, as well as on homepage, when the time comes. As the mission's name suggests, Ax-4 will be Axiom Space's fourth crewed trip to the ISS. Its astronauts will launch aboard a brand-new SpaceX Crew Dragon capsule, which will earn its wings on the flight. Ax-4 is led by commander Peggy Whitson, a former NASA astronaut who is currently Axiom's director of human spaceflight. Whitson has spent 675 days in space to date, more than any other American. The mission's other three crewmembers are pilot Shubhanshu Shukla of India; Polish mission specialist Sławosz Uznański of the European Space Agency; and mission specialist Tibor Kapu of Hungary. These latter three will make history on Ax-4, becoming the first people from their respective countries to live on board the ISS. Related stories: — SpaceX Dragon carrying Ax-3 astronauts splashes down in Atlantic to end longest private spaceflight for Axiom Space — Axiom Space: Building the off-Earth economy — Axiom Space eyes the moon while continuing to dream big in Earth orbit The Ax-4 astronauts will spend about two weeks living and working on the orbiting lab. They'll conduct 60 scientific experiments during that time — more than any previous Axiom Space mission has performed. The mission will end with a splashdown in the Pacific Ocean. Ax-4's return date has not yet been set; it will depend on weather conditions in the splashdown zone. Editor's note: This story was updated at 12:30 p.m. ET on Monday (June 9) with the new target launch date of Wednesday (June 11).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store